This week, Canada achieved a milestone in medicinal psychedelics as it granted authorization to a fledgling company to export these compounds. Read More

Research into LSD, psilocybin, and other psychedelics is accelerating, as biotech firms race to develop new drugs based on these substances. Read More

New research has found that psilocybin tends to inspire the belief that animals, plants and even inanimate objects have consciousness. Read More

Here are the common "best practices" of successful canna-businesses. A solid marijuana investment starts with this foundation. Read More

The Department of Justice is seeking public input on the "distinct economic impacts" of its plan to reclassify pot. Big money is at stake. Read More

The “next big thing” in the booming psychotropics industry? Tourist packages predicated on LSD, magic mushrooms, and other psychedelic drugs. Read More

We questioned one of the world’s top biotech investment strategists about the increasing monetization of psychedelics. Read More

The recent decision by the U.S. Drug Enforcement Administration (DEA) to shift cannabis to Schedule III is on its way to becoming reality. Read More

The DEA's reclassification of marijuana would substantially enhance the profitability and social acceptance of weed companies. Read More

According to news reports this week, the DEA intends to reevaluate restrictions on marijuana, recognizing its medical benefits. Read More